woman looking at her big pants with a smile, showing that she has lost a lot of weight

Zepbound And Wegovy: A Detailed Comparison Guide

Zepbound and Wegovy are injectable medications for weight management in adults with obesity or overweight. Zepbound, a dual GIP/GLP-1 receptor agonist, may offer greater weight loss than Wegovy, which targets GLP-1. Both require weekly injections and have similar side effects like nausea and diarrhea. Zepbound’s estimated monthly cost is $1060, while Wegovy’s is $1350. Insurance coverage varies. The best choice depends on individual factors like medical history, side effect tolerance, and cost, with consultation from a healthcare professional recommended.

In recent years, the landscape of pharmaceutical treatments for obesity and related metabolic conditions has expanded dramatically. In this environment, two relatively new entrants have attracted significant attention: Zepbound and Wegovy. Both aim to help patients achieve meaningful weight loss, but they are not identical in their formulations, mechanisms, dosing schedules, or side effects.

In this comprehensive guide, we will delve into how each medication works, their similarities and differences, their side effects, and even issues of cost and insurance coverage. By the end, you’ll have a clearer understanding of which of these might be the right path for you or someone you care for.

Get At-Home Medical Weight Loss Therapy

Lose weight with tirzepatide weight loss injections (the same ingredient in Zepbound & Mounjaro). If you are eligible, in-home medical weight loss treatments may help you reach your health goals.

Zepbound and Wegovy: Understanding the Basics

Zepbound and Wegovy are both injectable medications designed to aid in significant weight loss. While both belong to a broader category of drugs that help regulate appetite and metabolism, their specific mechanisms and chemical compositions are not identical. Understanding the fundamentals can help patients and healthcare providers determine which might be the better choice for a given scenario.

Zepbound and Wegovy work slightly differently

Zepbound is a brand name for a medication based on tirzepatide, which is approved for weight management in adults who struggle with obesity or who are overweight and have additional health complications. Tirzepatide is known as a GIP/GLP-1 receptor agonist. That is, it binds to and activates receptors for two key hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These hormones help regulate blood sugar and appetite. 

scale and a measuring tape

By working on two pathways instead of just one, Zepbound can potentially offer more significant weight loss effects compared to drugs that only affect the GLP-1 pathway. 1 Wegovy, on the other hand, is a brand name for semaglutide, a medication approved specifically for weight management. It primarily acts as a GLP-1 receptor agonist. GLP-1 is a hormone that signals feelings of fullness, slows stomach emptying, and reduces appetite, leading to decreased caloric intake and, subsequently, weight loss. 2 While effective, Wegovy’s mechanism is slightly more limited than Zepbound’s dual action, focusing on just the GLP-1 pathway.

Zepbound and Wegovy: similarities and differences

Both Zepbound and Wegovy are given via subcutaneous (under the skin) injection and are indicated for long-term treatment rather than short-term weight loss. They both work best when combined with dietary changes, increased physical activity, and lifestyle modifications. However, their differences come down to the complexity of their hormonal action, dosing schedules, side effect profiles, and the rate at which weight loss tends to occur.

In essence, while Wegovy leverages the GLP-1 pathway, Zepbound harnesses both GIP and GLP-1, potentially leading to more pronounced metabolic effects. That said, each person’s body chemistry is unique, and some may respond better to one medication over the other.

Zepbound and Wegovy have different FDA-approved uses

While both drugs aim at assisting with weight loss, the nuances of their approved uses can differ. Wegovy is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or those overweight (BMI ≥27) with at least one weight-related health condition (such as high blood pressure, Type 2 diabetes, or high cholesterol). 3 It is also cleared for adolescent use under certain conditions. 4

Zepbound, being tirzepatide indicated for obesity management, is currently approved for adults with obesity or overweight plus additional metabolic complications. 5 Its approval scenario largely mirrors Wegovy’s, but exact indications and labeling may vary slightly. Over time, and with more clinical studies, these indications may broaden to include or exclude certain populations.

Zepbound and Wegovy Have Similar Side Effects

Like most medications, both Zepbound and Wegovy can have side effects. Many of these stem from their influence on the gastrointestinal system, as both drugs slow digestion and alter hunger cues. Understanding potential side effects can help patients be better prepared and also inform conversations with their healthcare providers.

Common side effects of Zepbound and Wegovy

For both medications, common side effects often include: 1 2

Nausea

Feeling queasy or an unsettled stomach is the most frequently reported side effect. As the body adapts to the medication, nausea often subsides.

Diarrhea

Changes in gut motility can lead to loose stools.

Constipation

Paradoxically, while some experience diarrhea, others might find their bowel movements slow down.

Vomiting

Occasionally, patients may experience vomiting if their body reacts strongly to the dosage or if they eat too large a meal after an injection.

Abdominal pain or discomfort

Mild to moderate stomach cramps or discomfort may occur as the gastrointestinal system adjusts.

Many patients find these side effects are most pronounced when starting the medication or when increasing the dose. Gradually titrating up as recommended by healthcare providers often helps minimize these issues.

Serious side effects of Zepbound and Wegovy

While rare, serious side effects may occur: 1 2

Pancreatitis

Inflammation of the pancreas can manifest as severe abdominal pain, persistent nausea, and vomiting.

Gallbladder problems

Some patients experience gallstones or inflammation of the gallbladder, presenting as right upper quadrant abdominal pain, fever, or jaundice.

Kidney problems

Changes in fluid status and blood sugar can impact kidney function.

Allergic reactions

Though uncommon, severe allergic responses may include rash, difficulty breathing, or swelling of the face and throat.

If any severe side effects occur, patients should seek medical attention promptly.

Do Ozempic, Wegovy, Mounjaro, and Zepbound cause hair loss?

Hair loss is not typically a direct, commonly reported side effect of GLP-1 or GIP/GLP-1 agonists like Wegovy, Zepbound, Ozempic, or Mounjaro. However, some individuals report hair thinning or shedding after significant weight loss. This phenomenon often stems from rapid weight changes rather than the medication itself. When the body undergoes substantial shifts in nutrition, metabolism, or hormones, hair growth cycles can be temporarily disrupted. 6

If you notice unusual hair loss, consider discussing it with a healthcare provider. They may suggest dietary adjustments, supplements, or other strategies to ensure adequate nutrient intake and reduce the stress on the body that may be causing hair thinning.

The Basics of Zepbound vs. Wegovy for Weight Loss

Both Zepbound and Wegovy can yield significant weight loss when combined with lifestyle changes. Yet, there’s a perception supported by emerging studies that Zepbound may have a slight edge in overall weight reduction percentages, potentially because it activates two hormonal pathways rather than one.

Zepbound might cause more weight loss than Wegovy

Preliminary research and early clinical data suggest that patients taking Zepbound (tirzepatide) may achieve slightly greater weight loss than those on Wegovy (semaglutide). These differences are not guaranteed and depend heavily on individual factors such as adherence to dietary recommendations, exercise routines, and baseline metabolic conditions. However, the dual action of Zepbound makes it an attractive option for some patients, especially those who have had limited success with GLP-1-only therapies.

Woman looking at her big pants excited for the achived weight loss

Zepbound clinical trials

Clinical trials for tirzepatide have shown, on average, impressive weight reduction results, with some patients losing 15% to over 20% of their body weight. 7 8 These trials, which included large numbers of participants over many months, consistently found that tirzepatide helps reduce body weight more than placebo and, in many cases, more than semaglutide. 9 Yet, the results always have individual variation. Some patients might lose more, with others losing less. The key advantage for many is that Zepbound’s dual-action mechanism can lead to improved metabolic outcomes beyond weight loss alone, including better glucose control and potentially improved cardiovascular health markers.

How long until I lose weight on Wegovy?

Wegovy patients often begin noticing modest weight loss within the first month or two. More significant reductions, however, typically become evident after 3 to 6 months of consistent use. 10 Over a year, clinical trials have shown that Wegovy can help people lose, on average, around 15% of their initial body weight 11—though again, individual responses vary widely. Consistency and patience are essential. It is not uncommon for progress to be incremental rather than dramatic early on.

Wegovy clinical trials

Wegovy’s clinical trials demonstrated that many participants could achieve 10-15% weight reduction within a year 11, especially when combined with diet and exercise. These trials have firmly placed Wegovy among the top contenders for pharmacological weight management. Even though Zepbound may inch ahead in overall efficacy, Wegovy remains a proven and reliable option with a robust track record of safety and effectiveness.

Zepbound and Wegovy Have Different Doses

Both medications are administered via a pre-filled injection pen but follow distinct dosing schedules and escalation patterns. Understanding these nuances is essential, as following the correct dosage regimen is key to minimizing side effects and optimizing results.

Zepbound dosing

Zepbound’s dosing follows a gradual escalation approach to help the body adjust and reduce gastrointestinal side effects. Typically, patients start at a low dose and slowly work their way up over several weeks. Each dose is taken once weekly, at about the same time each week. A healthcare provider will guide patients through the dosing increments, which generally range from a starting dose of a low milligram amount up to the target maintenance dose that provides the maximum therapeutic effect.

Because tirzepatide has dual mechanisms, healthcare providers may be more cautious with dose escalations. Some patients may remain on intermediate doses if side effects become bothersome or if the desired weight loss occurs at a lower dose.

Wegovy dosing

Wegovy also uses a once-weekly injection schedule and a gradual titration plan. Patients typically start on a low dose of semaglutide and step up to higher doses every 4 weeks until reaching the full maintenance dose of 2.4 mg. This incremental approach allows the body to get used to the medication and reduces the likelihood of severe gastrointestinal side effects.

Adults

Both drugs are currently indicated for adult use. While Wegovy has some provisions for use in adolescents (approved for certain age groups meeting specific criteria), Zepbound’s use in younger populations is more limited at this time. Anyone considering these medications should verify the age criteria, as well as medical necessity, before starting treatment.

Making up for missed doses

Life can get hectic, and it is not uncommon to occasionally miss an injection. For Wegovy, if you miss a dose and your next scheduled dose is more than 2 days (48 hours) away, you should take the missed dose as soon as possible. However, if the next dose is less than 2 days away, skip the missed dose and resume your regular schedule.

Zepbound, on the other hand, has a slightly different approach to missed doses. If you miss a dose of Zepbound, administer it as soon as possible within 4 days of the scheduled time. If more than 4 days have passed, skip the missed dose and wait until your next regularly scheduled injection.

For both medications, if more than 2 weeks have elapsed since your last dose, contact your medical provider about how to restart your treatment.

Can you switch from Zepbound to Wegovy, or vice versa?

Switching from one medication to another is possible, but it should only be done under the guidance of a healthcare professional. Various factors influence this decision: how well you have tolerated the drug so far, what kind of weight loss or glycemic control you have achieved, and whether your insurance or budget supports one medication more than the other.

Transitions usually involve a brief washout period or careful dose adjustments to ensure safety and mitigate side effects. If you are contemplating a switch, discuss it thoroughly with your doctor. They may recommend additional tests or monitoring to ensure the switch does not negatively impact your progress.

The Cost of Wegovy vs. Zepbound

Medication costs are a critical factor for many patients, and these new weight loss drugs are often quite expensive without insurance. As per GoodRx as of the time of this article’s writing, Wegovy has an estimated monthly cost of $1350, while Zepbound has an estimated monthly cost of $1060. Pricing can vary widely depending on your location, insurance plan, and available manufacturer discounts or coupons.

Insurance coverage for Wegovy vs. Zepbound

Insurance companies are still evolving in how they approach coverage for obesity drugs. Some insurers readily cover Wegovy for patients meeting certain BMI and medical criteria, while others may be more restrictive. Coverage for Zepbound may be similar, though as a newer entry in the market, some insurers could be slower to add it to their formularies or impose stricter pre-authorization requirements.

It is possible that some plans will cover one but not the other, or place one medication in a more favorable coverage tier. Before you start either medication, it is wise to contact your insurer and request detailed information about coverage, copays, and any necessary medical documentation.

Ways to save money on Zepbound and Wegovy

If your insurance coverage is limited or nonexistent, there are still strategies to reduce costs:

  •     Manufacturer Coupons: Both Zepbound and Wegovy may offer coupons or trial offers.
  •     Patient Assistance Programs: Some pharmaceutical companies have income-based programs that provide medications at reduced cost or even for free.
  •     Pharmacy Shopping: Compare prices at different pharmacies or use online comparison tools. Prices can vary, and some may honor certain discount cards.
  •     Health Savings Accounts (HSAs): If you have a high-deductible insurance plan, using HSA funds can at least provide a tax-advantaged way to pay for medications.
  •     Generic or Biosimilar Options: In the future, when generics or biosimilars become available, costs may decrease.

Savings Card

Zepbound Savings Card

Manufacturers sometimes offer savings cards or coupons that can lower out-of-pocket costs, especially during the first months of treatment. A Zepbound Savings Card, if available, may significantly reduce the cost for eligible patients who meet certain criteria. It is always worth checking the official website or asking a healthcare provider for information on current discount programs.

Wegovy Savings Card

Like Zepbound, Wegovy’s manufacturer may offer a savings card or coupon. Patients meeting specific criteria can sometimes get substantial discounts on their copays. These discounts can make a big difference in early treatment, allowing patients to test the medication’s effectiveness before committing to higher long-term costs.

Which Weight Loss Drug Is Best?

When comparing drugs like Zepbound and Wegovy, patients often have broader inquiries about their overall health, other medications, and which weight loss drug might be best for them.

Determining “the best” weight loss drug is a highly individualized process. Factors to consider include:

Medical History

Do you have Type 2 diabetes, heart problems, or other chronic conditions that might make one drug more beneficial or safer?

Side Effect Tolerance

If you are particularly sensitive to nausea or other gastrointestinal side effects, you may prefer a drug whose side effects you have found more manageable.

Cost and Coverage

If your insurance only covers Wegovy, that may tilt the scales in favor of that option.

Personal Response

Sometimes, it is a matter of trial and error. If you tried Wegovy and lost minimal weight, you may find Zepbound more effective—or vice versa.

The best approach is to have an open, thorough conversation with a healthcare professional who knows your medical history and can weigh the pros and cons tailored to your situation.

How to Compare Injectable Weight Loss Drugs

When comparing injectable weight loss drugs, consider the following criteria:

Mechanism of Action

GLP-1-only vs. dual GIP/GLP-1 agonists. Understanding the pharmacological differences can guide you toward a therapy that might offer greater benefits.

Efficacy

Look at average weight loss percentages from clinical trials. While trial results are averages and may not predict your exact response, they offer a baseline expectation.

Side Effects

All drugs have potential downsides. Research what side effects are most common and consider whether you can tolerate them.

Long-Term Data

Not all medications have the same longevity of research. Drugs with more established track records might offer more confidence in their safety and efficacy over time.

Dosing Schedule and Flexibility

Some prefer a once-weekly shot on a predictable schedule; others value a medication that’s forgiving of missed doses.

Comparison Table

Below is a table recapping the major points discussed in this guide. This comparison aims to give you a quick at-a-glance overview of Zepbound vs. Wegovy regarding dosing, cost, type of drug, effectiveness, and more.

Aspect Zepbound Wegovy
Active Ingredient Tirzepatide Semaglutide
Drug Class GIP/GLP-1 receptor agonist GLP-1 receptor agonist
FDA-Approved Uses Chronic weight management in adults with obesity or overweight + certain health conditions Chronic weight management in adults with obesity or overweight + certain health conditions; some adolescent approval
Mechanism of Action Dual action: targets GIP and GLP-1 receptors Single pathway: targets GLP-1 receptors
Average Weight Loss Potentially higher (up to ~15-20% in some trials) ~10-15% average over one year
Dosing Schedule Once-weekly injection; gradual dose escalation Once-weekly injection; gradual dose escalation to 2.4 mg
Missed Dose Flexibility Can make up dose within 4 days Can make up dose within 2 days
Common Side Effects Nausea, diarrhea, constipation, vomiting Nausea, diarrhea, constipation, vomiting
Serious Risks Pancreatitis, gallbladder issues, possible allergic reactions Pancreatitis, gallbladder issues, possible allergic reactions
Hair Loss Not a common side effect; may occur due to rapid weight loss Not a common side effect; may occur due to rapid weight loss
Insurance Coverage Varies; newer drugs may face more coverage hurdles Varies; more established coverage patterns
Savings Programs Zepbound Savings Card possible Wegovy Savings Card available
Transition Between Drugs Possible under medical supervision Possible under medical supervision
Cost (Out-of-Pocket) Potentially high, estimated monthly cost of $1060, subject to discounts Potentially high, estimated monthly cost of $1350, subject to discounts

Conclusion

Zepbound and Wegovy represent two cutting-edge options in the pharmacological toolbox for weight management. Both have shown substantial promise, helping patients shed significant excess weight and potentially improve their overall metabolic health. Zepbound’s dual GIP/GLP-1 mechanism may give it a slight edge in certain cases, offering greater weight loss potential. Wegovy, with a strong track record and slightly more flexible dosing forgiveness, remains a tried-and-true option.

Your choice between the two may hinge on factors such as insurance coverage, tolerability of side effects, individual medical conditions, and long-term health goals. No one solution fits all. By maintaining open communication with a healthcare provider, evaluating personal responses to therapy, and staying informed about cost-saving measures, patients can find the medication that best suits their unique needs. The most important step is making an informed, personalized decision, guided by professional insight and clinical evidence.

Achieve Your Ideal Body with Tirzepatide

Discover the power of Tirzepatide (found in Zepound and Mounjaro), celebrated for driving consistent and meaningful weight loss. Embark on your weight management journey with confidence.

Start with a simple online consultation and comprehensive health evaluation, followed by necessary lab testing. Qualified participants will be prescribed medical weight loss treatments, conveniently shipped right to your home.

References

[1] Farzam, Khashayar, and Preeti Patel. 2024. “Tirzepatide.” StatPearls - NCBI Bookshelf. February 20, 2024.;

[2] Kommu, Sharath, and Philip Whitfield. 2024. “Semaglutide.” StatPearls - NCBI Bookshelf. February 11, 2024.;

[3] U.S. Food and Drug Administration. 2021. “FDA News Release: FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014.” June 3, 2021. ;

[4] U.S. Food and Drug Administration. 2024. “FDA News Release: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight.” March 8, 2024. ;

[5] U.S. Food and Drug Administration. 2023. “FDA News Release: FDA Approves New Medication for Chronic Weight Management.” November 9, 2023. ;

[1] Farzam, Khashayar, and Preeti Patel. 2024. “Tirzepatide.” StatPearls - NCBI Bookshelf. February 20, 2024.;

[2] Kommu, Sharath, and Philip Whitfield. 2024. “Semaglutide.” StatPearls - NCBI Bookshelf. February 11, 2024.;

[1] Farzam, Khashayar, and Preeti Patel. 2024. “Tirzepatide.” StatPearls - NCBI Bookshelf. February 20, 2024.;

[2] Kommu, Sharath, and Philip Whitfield. 2024. “Semaglutide.” StatPearls - NCBI Bookshelf. February 11, 2024.;

[6] Drugs.com Anderson December 24 “Do Ozempic, Wegovy, Mounjaro & Zepbound cause hair loss?” ;

[7] Jastreboff, Ania M., Louis J. Aronne, Nadia N. Ahmad, Sean Wharton, Lisa Connery, Breno Alves, Arihiro Kiyosue, et al. 2022. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine 387 (3): 205–16. ;

[8] Aronne, Louis J., Naveed Sattar, Deborah B. Horn, Harold E. Bays, Sean Wharton, Wen-Yuan Lin, Nadia N. Ahmad, et al. 2023. “Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity.” JAMA 331 (1): 38.;

[9] Rodriguez, Patricia J., Brianna M. Goodwin Cartwright, Samuel Gratzl, Rajdeep Brar, Charlotte Baker, Ty J. Gluckman, and Nicholas L. Stucky. 2024. “Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.” JAMA Internal Medicine 184 (9): 1056.;

[10] Ghusn, Wissam, Alan De La Rosa, Daniel Sacoto, Lizeth Cifuentes, Alejandro Campos, Fauzi Feris, Maria Daniela Hurtado, and Andres Acosta. 2022. “Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.” JAMA Network Open 5 (9): e2231982.;

[11] Novo Nordisk Inc. 2024. “WEGOVY FULL PRESCRIBING INFORMATION.”;

[11] Novo Nordisk Inc. 2024. “WEGOVY FULL PRESCRIBING INFORMATION.”;